A short-term follow-up of glycemic and body weight changes in diabetic patients who replaced dipeptidyl peptidase-4 inhibitors with the sodium-glucose cotransporter 2 inhibitor empagliflozin

BACKGROUND: Sodium-glucose cotransporter 2 inhibitors (SGLT2is, gliflozins) are associated with lower all-cause mortality than other anti-diabetic agents in patients with type 2 diabetes. In patients who may benefit from SGLT2is, but cannot add them to a dipeptidyl peptidase-4 inhibitor (DPP4i, glip...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Ann Saudi Med
Egile Nagusiak: Huang, Chung-Huei, Huang, Yu-Yao, Hsu, Brend Ray-Sea
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: King Faisal Specialist Hospital and Research Centre 2018
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6302983/
https://ncbi.nlm.nih.gov/pubmed/30531176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5144/0256-4947.2018.420
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak